FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059093069> ?p ?o ?g. }

• W2059093069 endingPage "S230" @default.
• W2059093069 startingPage "S230" @default.
• W2059093069 abstract "Monthly cycles of A, 740–910 mg/m2, C, 120 mg/m2 were given on Day 1 & V, 5 mg/m2 weekly to 24 Stage IIIA/B & 23 stage IV NSCLC pts. After 2 cycles ACV, Stage III pts received 60 Gy chest RT. 67% stage III, 65% Stage IV responded to ACV. Median follow-ups for Stage III and IV pts are 31 & 15 mos; 1 year survivals are 53% & 60%, respectively. Median survival for Stage III is 16 mos and for Stage IV is estimated to be 17 mos. The spectrum of toxicities from ACV were similar in Stage III/IV pts. A was given on day 1 to protect from C toxicities. Though transient increases in serum creatinine ≥ 2 mg/m2 were noted, protracted elevations lasting beyond day 28 occurred in only 6% (3/47). 11 stage IV pts received ≥ 4 cycles therapy. None sustained ≥ 40% reduction from baseline creatinine clearance (CrCl). This is in contrast to other trials using ≥ 4 cycles of 100 mg/m2 C in which 30–45% of the pts sustained ≥ 40% decrease in CrCl. Grade 4 neutropenia primarily related to weekly V given without A occurred in 46% of cycles. Toxicities from A were nausea/vomiting & transient hypotension. We conclude that amifostine appears to improve the therapeutic index of CV in NSCLC as evidenced by both high response rates & reduced cumulative renal toxicity. This is being tested in a multicenter randomized trial. Monthly cycles of A, 740–910 mg/m2, C, 120 mg/m2 were given on Day 1 & V, 5 mg/m2 weekly to 24 Stage IIIA/B & 23 stage IV NSCLC pts. After 2 cycles ACV, Stage III pts received 60 Gy chest RT. 67% stage III, 65% Stage IV responded to ACV. Median follow-ups for Stage III and IV pts are 31 & 15 mos; 1 year survivals are 53% & 60%, respectively. Median survival for Stage III is 16 mos and for Stage IV is estimated to be 17 mos. The spectrum of toxicities from ACV were similar in Stage III/IV pts. A was given on day 1 to protect from C toxicities. Though transient increases in serum creatinine ≥ 2 mg/m2 were noted, protracted elevations lasting beyond day 28 occurred in only 6% (3/47). 11 stage IV pts received ≥ 4 cycles therapy. None sustained ≥ 40% reduction from baseline creatinine clearance (CrCl). This is in contrast to other trials using ≥ 4 cycles of 100 mg/m2 C in which 30–45% of the pts sustained ≥ 40% decrease in CrCl. Grade 4 neutropenia primarily related to weekly V given without A occurred in 46% of cycles. Toxicities from A were nausea/vomiting & transient hypotension. We conclude that amifostine appears to improve the therapeutic index of CV in NSCLC as evidenced by both high response rates & reduced cumulative renal toxicity. This is being tested in a multicenter randomized trial." @default.
• W2059093069 created "2016-06-24" @default.
• W2059093069 creator A5022028594 @default.
• W2059093069 creator A5031189568 @default.
• W2059093069 creator A5041107550 @default.
• W2059093069 creator A5050185260 @default.
• W2059093069 creator A5063199899 @default.
• W2059093069 creator A5078587984 @default.
• W2059093069 date "1995-11-01" @default.
• W2059093069 modified "2023-09-27" @default.
• W2059093069 title "1106 Amifostine (A), cisplatin (C), Vinblastine (V): A highly active regimen for non small cell lung cancer (NSCLC)" @default.
• W2059093069 doi "https://doi.org/10.1016/0959-8049(95)96352-e" @default.
• W2059093069 hasPublicationYear "1995" @default.
• W2059093069 type Work @default.
• W2059093069 sameAs 2059093069 @default.
• W2059093069 citedByCount "0" @default.
• W2059093069 crossrefType "journal-article" @default.
• W2059093069 hasAuthorship W2059093069A5022028594 @default.
• W2059093069 hasAuthorship W2059093069A5031189568 @default.
• W2059093069 hasAuthorship W2059093069A5041107550 @default.
• W2059093069 hasAuthorship W2059093069A5050185260 @default.
• W2059093069 hasAuthorship W2059093069A5063199899 @default.
• W2059093069 hasAuthorship W2059093069A5078587984 @default.
• W2059093069 hasConcept C126322002 @default.
• W2059093069 hasConcept C126894567 @default.
• W2059093069 hasConcept C141071460 @default.
• W2059093069 hasConcept C146357865 @default.
• W2059093069 hasConcept C151730666 @default.
• W2059093069 hasConcept C2777063308 @default.
• W2059093069 hasConcept C2778496288 @default.
• W2059093069 hasConcept C2779387952 @default.
• W2059093069 hasConcept C2780306776 @default.
• W2059093069 hasConcept C2780580376 @default.
• W2059093069 hasConcept C2781413609 @default.
• W2059093069 hasConcept C29730261 @default.
• W2059093069 hasConcept C71924100 @default.
• W2059093069 hasConcept C86803240 @default.
• W2059093069 hasConcept C90924648 @default.
• W2059093069 hasConceptScore W2059093069C126322002 @default.
• W2059093069 hasConceptScore W2059093069C126894567 @default.
• W2059093069 hasConceptScore W2059093069C141071460 @default.
• W2059093069 hasConceptScore W2059093069C146357865 @default.
• W2059093069 hasConceptScore W2059093069C151730666 @default.
• W2059093069 hasConceptScore W2059093069C2777063308 @default.
• W2059093069 hasConceptScore W2059093069C2778496288 @default.
• W2059093069 hasConceptScore W2059093069C2779387952 @default.
• W2059093069 hasConceptScore W2059093069C2780306776 @default.
• W2059093069 hasConceptScore W2059093069C2780580376 @default.
• W2059093069 hasConceptScore W2059093069C2781413609 @default.
• W2059093069 hasConceptScore W2059093069C29730261 @default.
• W2059093069 hasConceptScore W2059093069C71924100 @default.
• W2059093069 hasConceptScore W2059093069C86803240 @default.
• W2059093069 hasConceptScore W2059093069C90924648 @default.
• W2059093069 hasLocation W20590930691 @default.
• W2059093069 hasOpenAccess W2059093069 @default.
• W2059093069 hasPrimaryLocation W20590930691 @default.
• W2059093069 hasRelatedWork W1980701009 @default.
• W2059093069 hasRelatedWork W1985540222 @default.
• W2059093069 hasRelatedWork W2073551076 @default.
• W2059093069 hasRelatedWork W2093208639 @default.
• W2059093069 hasRelatedWork W2243375749 @default.
• W2059093069 hasRelatedWork W2316688895 @default.
• W2059093069 hasRelatedWork W2362108816 @default.
• W2059093069 hasRelatedWork W2382265168 @default.
• W2059093069 hasRelatedWork W2389233550 @default.
• W2059093069 hasRelatedWork W2864608773 @default.
• W2059093069 hasVolume "31" @default.
• W2059093069 isParatext "false" @default.
• W2059093069 isRetracted "false" @default.
• W2059093069 magId "2059093069" @default.
• W2059093069 workType "article" @default.